Mesenchymal stem cells (MSCs) have multiple functions, including tissue repair, immune regulation, promotion of angiogenesis, anti-apoptosis, antioxidant, anti-fibrosis, and homing. They hold great potential in the treatment of various diseases such as autoimmune disorders, lung diseases, and tissue injury.

MSCs derived from induced pluripotent stem cells (iPSCs) (iMSCs) have several advantages over traditional MSCs, including large batch production, consistent quality, stable efficacy, and ease of genetic modification.

Nuwacell currently has three iMSC-based cell therapy products in clinical trial stages. Among them, “NCR100” is the first iMSC product approved for clinical trials in China, while “NCR101” is the world’s first gene-modified iMSC product to receive clinical trial approval. Moving forward, Nuwacell will continue to develop iMSC-based therapies targeting a broad range of indications.